RNAi
Silence Therapeutics Looks to Raise $120M in Oversubscribed Private Placement
The firm will use the proceeds to advance its pipeline products, such as zerlasiran in people with elevated Lp(a) at high risk of cardiovascular events.
Arrowhead Pharmaceuticals Readying to Kick Off Phase I SOD1-ALS Drug Trial
ARO-SOD1 is an RNAi-based therapy that aims to reduce expression of the SOD1 gene in the central nervous system of ALS patients.
Sirnaomics Launches Phase I/II Trial of RNAi Therapeutic for Facial Skin Cancer Lesions
The company will look for biomarkers in the TGF-B1 and COX-2 genes, which are overexpressed in squamous cell skin cancer.